PMID- 35784948
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Electronic)
IS  - 2049-0801 (Linking)
VI  - 79
DP  - 2022 Jul
TI  - Heparin for patients with coronavirus disease 2019 and hypercoagulation 
      complications: A cohort study.
PG  - 104042
LID - 10.1016/j.amsu.2022.104042 [doi]
LID - 104042
AB  - BACKGROUND: Thrombotic complications of coronavirus disease 2019 (COVID-19) are a 
      worrisome aspect of the disease due to their high incidence in critically ill 
      patients and their poor clinical outcomes. The aim of this study was to compare 
      the effectiveness of unfractionated heparin (UFH) and low molecular weight 
      heparin (LMWH) (fondaparinux) in hospitalized COVID-19 patients with 
      hypercoagulable complications. MATERIAL AND METHODS: The study design used a 
      retrospective cohort approach incorporating pre- and post-tests via secondary 
      data extracted from the medical records of inpatients with confirmed COVID-19. 
      RESULTS: Among the 98 individuals studied (52% women; 30.6% at >60 years of age), 
      35 patients received UFH, while the remaining 63 patients received LMWH 
      (fondaparinux). The greatest decrease in the D-dimer value (0.01 +/- 0.5 g 
      fibrinogen equivalent units/mL) was observed in 12 (34.3%) and 15 (23.8%) 
      patients in the UFH and LMWH (fondaparinux) groups, respectively. Most inpatients 
      with confirmed COVID-19 were aged 50-59 years and were women. CONCLUSION: There 
      was a tendency toward increased D-dimer, normal prothrombin time, normal 
      activated partial thromboplastin clotting time, and increased fibrinogen values 
      in each COVID-19 patient. The results demonstrated a significant relationship 
      between the D-dimer and prothrombin time parameter in confirmed COVID-19 
      inpatients.
CI  - (c) 2022 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
FAU - Fachri, Muhammad
AU  - Fachri M
AD  - Department of Pulmonology and Respiratory Medicine, Faculty of Medicine and 
      Health, Universitas Muhammadiyah Jakarta, Jakarta, Indonesia.
FAU - Hatta, Mochammad
AU  - Hatta M
AD  - Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin 
      University, Makassar, Indonesia.
FAU - Tarigan, Sefia Nabila Nur Azmi
AU  - Tarigan SNNA
AD  - Department of Pulmonology and Respiratory Medicine, Faculty of Medicine and 
      Health, Universitas Muhammadiyah Jakarta, Jakarta, Indonesia.
FAU - Akaputra, Risky
AU  - Akaputra R
AD  - Department of Pulmonology and Respiratory Medicine, Faculty of Medicine and 
      Health, Universitas Muhammadiyah Jakarta, Jakarta, Indonesia.
FAU - Dwiyanti, Ressy
AU  - Dwiyanti R
AD  - Department of Forensic and Medicolegal, Faculty of Medicine, Hasanuddin 
      University, Makassar, Indonesia.
AD  - Department of Medical Microbiology, Faculty of Medicine, Tadulako University, 
      Palu, Indonesia.
FAU - Syukri, Ahmad
AU  - Syukri A
AD  - Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin 
      University, Makassar, Indonesia.
AD  - Postgraduate School, Faculty of Medicine, Hasanuddin University, Makassar, 
      Indonesia.
FAU - Junita, Ade Rifka
AU  - Junita AR
AD  - Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin 
      University, Makassar, Indonesia.
AD  - Postgraduate School, Faculty of Medicine, Hasanuddin University, Makassar, 
      Indonesia.
FAU - Primaguna, Muhammad Reza
AU  - Primaguna MR
AD  - Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, 
      Makassar, Indonesia.
FAU - Febrianty, Andini
AU  - Febrianty A
AD  - Department of Forensic and Medicolegal, Faculty of Medicine, Hasanuddin 
      University, Makassar, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20220628
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC9238275
OTO - NOTNLM
OT  - COVID-19
OT  - D-dimer
OT  - Heparin
OT  - Hypercoagulation
OT  - LMWH (Fondaparinux)
COIS- The authors declare no conflict of interest, financial or otherwise.
EDAT- 2022/07/06 06:00
MHDA- 2022/07/06 06:01
PMCR- 2022/06/28
CRDT- 2022/07/05 10:32
PHST- 2022/05/09 00:00 [received]
PHST- 2022/06/17 00:00 [revised]
PHST- 2022/06/18 00:00 [accepted]
PHST- 2022/07/05 10:32 [entrez]
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/07/06 06:01 [medline]
PHST- 2022/06/28 00:00 [pmc-release]
AID - S2049-0801(22)00802-0 [pii]
AID - 104042 [pii]
AID - 10.1016/j.amsu.2022.104042 [doi]
PST - ppublish
SO  - Ann Med Surg (Lond). 2022 Jul;79:104042. doi: 10.1016/j.amsu.2022.104042. Epub 
      2022 Jun 28.